The purpose of the trial is to determine whether survodutide can lower the risk of serious liver‑related events and death in people with compensated cirrhosis due to NASH/MASH. Participants will receive the study injection each week for about a year and will attend regular clinic visits for safety checks, blood tests, and imaging. The main outcome looks at the time until the first occurrence of any major event such as liver transplant, death, hepatic decompensation (a worsening of liver function), a rise in the MELD score (a number that reflects how well the liver works) to 15 or higher, or the development of CSPH (high blood pressure in the vessels of the liver). Additional measurements include changes in the ELF score (a blood test that indicates liver scarring), body weight, blood sugar levels, and liver stiffness assessed by FibroScan (an ultrasound that measures how firm the liver is) and MRE (a type of MRI scan for the same purpose). Blood tests will also track liver enzymes AST and ALT, which rise when liver cells are damaged.

The main goal of the trial is to find out whether survodutide can improve liver health better than the placebo. “Improving liver health” means the disease may disappear without the scar tissue getting worse, and the scar tissue may become less severe. Terms such as MRI refer to a scan that uses magnets to create detailed pictures of the liver, while VCTE is a quick test that measures how stiff the liver is, which helps doctors see how much scarring is present.

Participants will receive the weekly injection for about one year and will attend regular visits where blood samples are taken, weight is measured, and imaging tests such as MRI and VCTE are performed. After the treatment period, they will continue to be followed for several more months to monitor long‑term safety and any changes in liver condition.

During the study, participants have regular check‑ups that include blood tests, a scan called MRI (which creates detailed pictures of internal organs) to measure spleen and liver size, and assessments of blood‑carrying protein (hemoglobin) and tiny blood‑clotting cells (platelet count). A questionnaire that looks at everyday skills and motor abilities is also completed. Blood samples are taken to measure substances that indicate disease activity, and any side effects or safety concerns are recorded throughout the study period.

The purpose of the study is to find out if the under‑skin injection works at least as well as the vein infusion in terms of how the drug moves through the body (pharmacokinetic). Participants are randomly assigned to one of the two ways of receiving the medicine and will visit the clinic regularly for blood tests, imaging scans to see the tumor, and safety checks. The trial lasts for several months, during which any side effects are recorded and managed.

The purpose of the study is to determine whether weekly injections of the drug improve nerve symptoms compared with the placebo. Participants will receive an injection each week for several months and will attend regular visits where doctors will check nerve function using a questionnaire called the mTCNS (a score that rates how severe the nerve problems are). Other questionnaires will also be used, such as the Norfolk QoL-DN (a quality‑of‑life survey for nerve disease), the clinESSDAI and ESSDAI (measures of overall disease activity), the NPQ (a questionnaire about pain), a NRS rating for difficulty thinking, and patient‑ and clinician‑rated impression scales (PGIS, PGIC, CGIS, and CGI). Fatigue will be measured with the FACIT-Fatigue questionnaire.

Throughout the study, safety will be monitored by checking vital signs, heart rhythm, blood tests, and any side effects that may occur. Participants will have the opportunity to report any adverse events, and the study team will evaluate the seriousness of any findings. The overall design allows comparison of the drug’s effect with the placebo while keeping participants and investigators unaware of which treatment is being given.

The purpose of this study is to continue providing treatment to patients who have completed a previous cancer study with Durvalumab and are still benefiting from it, according to their doctor. The study will monitor the safety and how well patients tolerate the treatment. In addition to Durvalumab, the study may also involve other medications such as Infliximab and Mycophenolate Mofetil, which are used for different purposes. Infliximab is administered through an infusion, while Mycophenolate Mofetil is taken orally in capsule form.

Participants in this study will continue to receive their treatment as long as they are benefiting from it. The study will keep track of any serious side effects that occur up to 90 days after the last dose of the study treatment. This trial aims to ensure that patients who are doing well on their current treatment can continue to receive it safely.

Participants are randomly assigned to receive either belumosudil tablets taken by mouth or one of the comparator medicines chosen by their doctor. The study lasts about 24 weeks, during which regular clinic visits are scheduled to check symptoms, perform blood tests, and assess overall health. Researchers look at the overall response rate, which means the percentage of people whose disease shows improvement, using standard doctor‑approved guidelines (NIH consensus response criteria). Systemic therapy refers to medicines that work throughout the whole body, and any need for new systemic treatment, relapse of the underlying disease, or death is recorded.

Throughout the trial, safety is closely monitored; blood samples are taken to measure drug levels and to watch for side effects. Participants can stop the study at any time if they experience problems. The information gathered will help determine whether belumosudil works better and is safe for people with this condition.

The purpose of the study is to see if GSK6042981 works better than sunitinib malate in slowing down the growth of the cancer or stopping it from getting worse. Patients taking part in this study will be randomly assigned to receive either GSK6042981 or sunitinib malate, and both groups will know which medicine they are receiving. During the study, doctors will monitor how well the treatment is working and how long patients can go without their disease getting worse. Patients will also be asked about their quality of life and any side effects they may experience.

Throughout the study, doctors will collect tissue samples from tumors for laboratory testing, which may come from previously stored tissue or from a new biopsy. The study will also measure the levels of GSK6042981 in the blood and track various aspects of patient health, including how long patients live, how quickly the tumor responds to treatment, and whether the cancer gets worse after starting a different treatment following the study medicine. Patients will complete questionnaires about their symptoms and overall well-being to help researchers understand how the treatments affect daily life.

The purpose of the study is to find out whether the spray can improve the sharpness of vision, known as visual acuity, compared with the placebo. Over several months, participants will use the spray daily and attend regular visits where standard eye tests are performed, such as reading letters on a chart, checking the area that can be seen without moving the eyes (visual field), and an eye scan called optical coherence tomography that measures the thickness of retinal layers. The study follows each person from the start of treatment through the end of the observation period to see how vision changes over time.

The purpose of the trial is to determine whether the new medicine works as well as, or better than, the standard treatment in patients who have not received prior therapy for this condition. This phase 3 investigation uses a randomized, open-label design, meaning participants are assigned by chance to one of the two drugs and both the study team and participants know which drug is being taken. After enrollment, participants receive daily medication and attend regular clinic visits for safety checks and imaging scans that monitor the tumor. The study follows each person until the cancer shows signs of worsening, which is measured as progression-free survival, or until side effects require stopping the medication.

The purpose of the study is to determine whether giving a single dose of Tocilizumab before the cancer drug ramantamig can lower the chance of this immune reaction compared with a placebo. Participants are randomly assigned to receive either the active medication or the inactive solution, and neither the medical team nor the participants know which one is given. After the injection, participants receive the cancer treatment and are observed for about four weeks for any signs of the immune reaction or other side effects.

The trial follows a double‑blind design, meaning the assignment is concealed, and it lasts until the end of the monitoring period after the first dose of the cancer drug. Safety checks, blood tests, and regular visits are used to record any problems that arise during the study.

The purpose of the trial is to evaluate the clinical efficacy of frevecitinib. Over a period of about three months, participants will take the study medication each day and attend clinic visits at the start of the study and at weeks 2, 4, 8 and 12. During these visits lung function will be measured using tests such as FEV1, which records how much air can be forced out of the lungs in one second, and symptom questionnaires will be completed.

Safety will be monitored throughout the study with regular checks of blood tests, heart rhythm recordings (ECG), blood pressure, and reports of any adverse events. Participants will continue their regular asthma inhalers while using the study powder, and any changes in rescue inhaler use or asthma symptoms will be recorded.

The purpose of the study is to see whether adding Rinatabart Sesutecan can keep the cancer from growing for a longer time compared with the usual treatment alone. Participants are randomly placed into one of the two groups after completing their second‑line chemotherapy, then they receive the assigned maintenance therapy for several months while doctors monitor their health through regular clinic visits and scans.

Progression‑free survival means the period during which the cancer does not get worse. Doctors use a set of rules called RECIST to measure whether tumors have grown or shrunk on imaging tests. To understand how the treatments affect overall well‑being, participants also complete a questionnaire known as the EORTC QLQ‑C30, which asks about symptoms, daily activities, and overall quality of life.

The purpose of the study is to determine the dose‑response relationship of UBT251, meaning how different amounts of the medicine change the level of HbA1c, a test that shows average blood sugar over the past few months, in people whose diabetes is not well controlled with metformin alone or together with a SGLT2 inhibitor.

Participants will receive weekly injections for about ten months and will attend regular clinic visits where blood samples are taken and body measurements are recorded. Some participants will receive the new drug, some will receive the existing drug, and some will receive the inactive substance. The study will track changes in blood sugar, weight, and other health markers over the course of the trial.

The purpose of the trial is to determine whether daily treatment with Engasertib reduces the frequency of epistaxis compared with placebo over a period of about 28 weeks. Participants will receive either the study drug or placebo each day, keep a simple diary to record each nosebleed event, and attend regular clinic visits where basic health checks and blood work are performed to monitor safety. The study is conducted in a double-blind manner, meaning that neither the participants nor the study staff know which treatment is being taken, which helps ensure unbiased results.

The purpose of the study is to find out whether giving Salanersen about six months after the gene‑therapy is safe and can be tolerated well. Children who take part will receive the injection and then be seen regularly for several years. At each visit they will have simple blood draws and brief examinations to check how they are doing.

During the study doctors will watch for any side effects and will also look at a protein called neurofilament light chain that can show nerve damage, and they will perform a test called compound muscle action potential that measures how nerves and muscles work together. The children’s ability to reach basic movement goals such as sitting, standing and walking will be recorded using the World Health Organization motor milestones and other easy‑to‑understand scales like the Hammersmith Infant Neurological Examination, CHOP INTEND, Hammersmith Functional Motor Scale Expanded and Revised Upper Limb Module. The follow‑up continues until the children are several years old, allowing researchers to see long‑term safety and any signs of benefit.

The purpose of this study is to evaluate how well XmAb942 works in helping people with moderately to severely active Ulcerative Colitis achieve clinical remission, which means bringing the disease under control so that symptoms improve significantly. The study is divided into two parts. The first part tests the medication in healthy volunteers to check its safety. The second part involves people who have moderate to severe Ulcerative Colitis and have not responded well to previous treatments, lost response to them, or could not tolerate them. Participants in the second part must have had Ulcerative Colitis for at least three months and show active disease with inflammation visible during examination of the bowel.

During the study, participants will be randomly assigned to receive either XmAb942 or placebo. The treatment period lasts up to 48 weeks, with an important assessment at week 12 to see if the medication is working. Doctors will measure improvement by looking at various signs of the disease, including bleeding, bowel movement frequency, and inflammation seen during bowel examination. The study will also monitor any side effects or unwanted reactions that occur during treatment to ensure the safety of participants.

The main aim of the trial is to assess the long‑term safety of the study drug, meaning how well it is tolerated over time and what side effects may occur. Participants who have already finished earlier studies receive the medication for an extended period, attending regular visits where health checks, blood tests and simple scans are performed. Any unwanted problems, called adverse events, are recorded and evaluated, with particular attention to serious issues that might require medical care.

During the trial, volunteers will receive the assigned injection at regular visits over several months. At each visit, doctors will check the skin’s condition and the level of itching using simple scales. One of the scales, called the EASI score, measures how much of the body is affected and how severe the rash is. Another assessment, the vIGA-AD, looks at overall disease activity, while the PP-NRS records how strongly the patient feels the itch each day. These checks help determine whether the medication improves the skin and reduces itching compared with the placebo.

The study follows participants for an extended period during which they receive regular injections of the medication and attend scheduled visits for health checks. At each visit, researchers record any side effects, which are referred to as adverse events, and collect questionnaire responses that measure changes in eye muscle strength, daily activity ability, and overall quality of life. The overall aim is to determine whether the medication is safe and tolerable for people living with this eye‑related form of myasthenia gravis.

The purpose of the study is to evaluate how well these new immunotherapy combinations work compared to Pembrolizumab alone in patients with a specific type of NSCLC that shows high levels of a protein called PD-L1. This protein can affect how the immune system responds to cancer. The study will involve participants receiving these treatments through an intravenous infusion, which means the medication is given directly into a vein. The study will follow participants over a period of time to observe the effects of the treatments on their cancer.

Participants in the study will be monitored closely by healthcare professionals to ensure their safety and to gather information about how the treatments are working. The study aims to provide valuable insights into the effectiveness of these new treatment combinations for NSCLC, potentially leading to better treatment options for patients in the future.

Participants are randomly assigned to receive either Sapablursen or the placebo, and neither the participants nor the study staff know which treatment is given (double‑blind). Throughout the study, regular blood tests are performed to measure the hematocrit level (the proportion of red blood cells in the blood). If the hematocrit rises above a certain level, a phlebotomy—a simple procedure where a small amount of blood is drawn to lower the count—may be needed. Researchers also ask participants to complete short questionnaires about fatigue and other symptoms to see how the treatment affects daily feeling. The trial lasts roughly 32 weeks, with visits scheduled at regular intervals to monitor safety, any side effects, and overall health.

Participants will receive a series of injections over a period of several weeks, with regular visits to the clinic where doctors will ask about eye symptoms, quality of life, and ability to perform daily activities. Simple questionnaires will be used to measure changes in eye muscle strength and overall well‑being. The study will also monitor any side effects that may occur during the treatment period.

The purpose of the study is to assess how safe the medicine is and whether it shows early signs that it can shrink tumors when used alone or with the hormone blocker. Participants start with low doses that are gradually increased while doctors watch for side effects, known as dose‑limiting toxicities, and determine the highest dose that can be given safely, called the maximum tolerated dose. After the safe dose is found, more patients receive that dose for several treatment cycles, with regular clinic visits, blood tests, and imaging scans to see if the tumors are responding. The study follows a phase 1/2 trial design, beginning with a safety‑focused part and then moving to a larger group to look at tumor response and how long the benefit lasts.

The purpose of the study is to describe the safety profile of the PG4 vaccine. Infants receive a single dose of either the study vaccine or the comparison vaccine and are then observed for a short time after the injection, followed by scheduled visits to check their health over the next weeks.

Researchers will watch for common side effects such as redness, swelling, pain at the injection site, fever, reduced appetite, irritability, or increased sleep. Any side effects, known as adverse events, and any serious side effects that require medical attention, called serious adverse events, will be recorded and reviewed.

The purpose of the study is to determine whether the new medicine works as well as the existing one. Participants will receive a series of these eye injections over several months and will have regular eye examinations. Vision will be checked using a test called BCVA, measured with an ETDRS chart, which is a standardized eye chart used to assess how well a person can read letters. Doctors will also look for signs of fluid inside the retina, called IRF and SRF, and will measure the size of the abnormal blood‑vessel area, known as CNV, using imaging methods such as FA and SD-OCT. Safety will be monitored throughout the study, including checking for any immune reactions called ADAs.

The purpose of the study is to compare how well BNT324 works against docetaxel in slowing disease progression and extending survival. Participants are randomly assigned to one of the two groups and receive the assigned medication in cycles, typically every three weeks, with treatment continuing until the disease worsens, side effects become too severe, or the planned treatment period ends.

During the trial, patients undergo regular imaging scans to check for changes in tumor size, blood tests to monitor prostate‑specific antigen levels, and assessments of pain and overall health. The study records how long the cancer remains stable, the time until death from any cause, and any side effects experienced.

The purpose of the study is to evaluate how effective imlunestrant is compared to these standard treatments in preventing the return of breast cancer in patients who have already received two to five years of standard endocrine therapy. Endocrine therapy is a treatment that helps to stop or slow the growth of cancer by blocking the body’s natural hormones. Participants in the study will be randomly assigned to receive either imlunestrant or one of the standard treatments. The study will monitor participants over a period of time to see how well the treatments work in preventing cancer from coming back.

Throughout the study, participants will receive regular check-ups and assessments to monitor their health and the effectiveness of the treatment. The study aims to provide valuable information on whether imlunestrant can offer a better option for patients with this type of breast cancer, potentially improving outcomes and reducing the risk of cancer recurrence. The study will also look at the overall health and quality of life of participants while they are receiving treatment.

During the 24‑week period, participants are randomly assigned to one of the two groups and neither the participants nor the study staff know which treatment is given (double‑blind). Regular visits include blood tests that measure NT-proBNP, a protein that rises when the heart is under stress, and imaging tests such as an ultrasound of the heart (echocardiogram) that assess measurements like left ventricular end-diastolic volume index, left ventricular end-systolic volume index, E/e′ ratio, global longitudinal strain and left atrial volume index. Participants also complete the Kansas City cardiomyopathy questionnaire to report symptoms and quality of life, and a routine 12‑lead Electrocardiogram is performed to check the heart’s electrical activity. Throughout the study, safety is monitored by recording any side effects and checking routine laboratory values.